Statements (34)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
PPARδ agonist |
| gptkbp:ATCCode |
none
|
| gptkbp:CASNumber |
317318-70-0
|
| gptkbp:category |
investigational drug
performance-enhancing drug |
| gptkbp:clinicalTrialPhase |
terminated due to safety concerns
|
| gptkbp:developedBy |
gptkb:Ligand_Pharmaceuticals
GlaxoSmithKline |
| gptkbp:discoveredIn |
1990s
|
| gptkbp:effect |
improves endurance in animal studies
increases fatty acid metabolism |
| gptkbp:hasMolecularFormula |
C21H18F3NO3S2
|
| https://www.w3.org/2000/01/rdf-schema#label |
GW501516
|
| gptkbp:intendedUse |
treatment of metabolic and cardiovascular diseases
|
| gptkbp:IUPACName |
2-(2-methyl-4-((2-(4-(trifluoromethyl)phenyl)thiazol-4-yl)methylthio)phenoxy)acetic acid
|
| gptkbp:legalStatus |
research chemical
|
| gptkbp:mechanismOfAction |
activates the peroxisome proliferator-activated receptor delta (PPARδ)
|
| gptkbp:molecularWeight |
453.5 g/mol
|
| gptkbp:otherName |
Cardarine
Endurobol |
| gptkbp:PubChem_CID |
7989376
9813757 CHEMBL193931 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
potential carcinogenicity
liver damage (in animal studies) |
| gptkbp:status |
not approved for human use
banned by World Anti-Doping Agency (WADA) |
| gptkbp:toxicity |
shown to cause cancer in animal studies
|
| gptkbp:UNII |
6LZ7XEZ0NC
|
| gptkbp:usedIn |
doping in sports
|
| gptkbp:bfsParent |
gptkb:SR_90003
|
| gptkbp:bfsLayer |
8
|